Sildenafil Teva

Country: European Union

Language: Maltese

Source: EMA (European Medicines Agency)

Active ingredient:

sildenafil

Available from:

Teva B.V. 

ATC code:

G04BE03

INN (International Name):

sildenafil

Therapeutic group:

Drogi użati f'każ ta 'disfunzjoni erettili

Therapeutic area:

Disfunzjoni erettili

Therapeutic indications:

Trattament ta 'rġiel b'funzjoni ta' disfunzjoni erettili, li hija l-inkapaċità li tikseb jew iżżomm erezzjoni tal-pene suffiċjenti għal prestazzjoni sesswali sodisfaċenti. Sabiex għal Sildenafil Teva ikun effettiv, hija meħtieġa stimulazzjoni sesswali.

Product summary:

Revision: 17

Authorization status:

Awtorizzat

Authorization date:

2009-11-30

Patient Information leaflet

                                29
B. FULJETT TA’ TAGĦRIF
30
FULJETT TA’ TAGĦRIF: INFORMAZZJONI GĦALL-PAZJENT
SILDENAFIL TEVA
25 MG PILLOLI MIKSIJA B’RITA
sildenafil
AQRA SEW DAN IL-FULJETT KOLLU QABEL TIBDA TIEĦU DIN IL-MEDIĊINA
PERESS LI FIH INFORMAZZJONI
IMPORTANTI GĦALIK
-
Żomm dan il-fuljett. Jista’ jkollok bżonn terġa’ taqrah.
-
Jekk ikollok aktar mistoqsijiet, staqsi lit-tabib, lill-ispiżjar jew
l-infermier tiegħek.
-
Din il-mediċina ġiet mogħtija lilek biss. M’għandekx tgħaddiha
lil persuni oħra. Tista’
tagħmlilhom il-ħsara, anki jekk ikollom l-istess sinjali ta’ mard
bħal tiegħek.
•
Jekk ikollok xi effett sekondarju kellem lit-tabib jew lill-ispiżjar
tiegħek. Dan jinkludi xi effett
sekondarju possibbli li m’huwiex elenkat f’dan il-fuljett. Ara
sezzjoni 4.
F’DAN IL-FULJETT
1.
X’inhu Sildenafil Teva u għalxiex jintuża
2.
X’għandek tkun taf qabel ma tieħu Sildenafil Teva
3.
Kif għandek tieħu Sildenafil Teva
4.
Effetti sekondarji possibbli
5.
Kif taħżen Sildenafil Teva
6.
Kontenut tal-pakkett u informazzjoni oħra
1.
X’INHU SILDENAFIL TEVA U GĦALXIEX JINTUŻA
Sildenafil Teva fih is-sustanza attiva sildenafil li jagħmel ma’
grupp ta’ mediċini li jissejħu impedituri
ta’ phosphodiesterase tip 5 (PDE5). Hu jaġixxi billi jgħin
jirrilassa l-vażi tad-demm fil-pene tiegħek, u
hekk jippermetti d-demm jidħol fil-pene meta tkun eċitat
sesswalment. Sildenafil Teva jgħinek biss
biex ikollok it-twebbis jekk tkun stimlat sesswalment.
Sildenafil Teva huwa trattament għal irġiel adulti li għandhom
problema biex jibbies il-pene, li kultant
imsejjħa impotenza. Dan jigri meta raġel ma jkunx jista’ jikseb,
jew iżomm, pene erett u iebes li jkun
adattat għal attività sesswali.
2.
X’GĦANDEK TKUN TAF QABEL MA TIEĦU SILDENAFIL TEVA
TIĦUX SILDENAFIL TEVA
•
Jekk inti allerġiku għal sildenafil jew għal xi sustanza oħra
ta’ din il-mediċina (elenkati fis-
sezzjoni 6).
•
Jekk inti qed tieħu mediċini li huma msejħa nitrati, minħabba li
flimkien jistgħu jikkawżaw
t
                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
ANNESS I
SOMMARJU TAL- KARATTERISTIĊI TAL-PRODOTT
2
1.
ISEM IL-PRODOTT MEDIĊINALI
Sildenafil Teva 25 mg pilloli miksija b’rita
Sildenafil Teva 50 mg pilloli miksija b’rita
Sildenafil Teva 100 mg pilloli miksija b’rita
2.
GĦAMLA KWALITATTIVA U KWANTITATTIVA
Sildenafil Teva 25 mg pilloli miksija b’rita
Kull pillola fiha sildenafil citrate ekwivalenti għal 25 mg ta’
sildenafil.
Sildenafil Teva 50 mg pilloli miksija b’rita
Kull pillola fiha sildenafil citrate ekwivalenti għal 50 mg ta’
sildenafil.
Sildenafil Teva 100 mg pilloli miksija b’rita
Kull pillola fiha sildenafil citrate ekwivalenti għal 100 mg ta’
sildenafil.
Għal-lista kompluta ta’ eċċipjenti, ara sezzjoni 6.1.
3.
GĦAMLA FARMAĊEWTIKA
Pillola miksija b’rita.
Sildenafil Teva 25 mg pilloli miksija b’rita
Pilloli bojod miksija b’rita, f’għamla ovali li fuqhom hemm
intaljat ‘S 25’ fuq naħa waħda, u mingħajr
disinn fuq in-naħa l-oħra.
Sildenafil Teva 50 mg pilloli miksija b’rita
Pilloli bojod miksija b’rita, f’għamla ovali li fuqhom hemm
intaljat ‘S 50’ fuq naħa waħda, u mingħajr
disinn fuq in-naħa l-oħra.
Sildenafil Teva 100 mg pilloli miksija b’rita
Pilloli bojod miksija b’rita, f’għamla ovali li fuqhom hemm
intaljat ‘S 100’ fuq naħa waħda, u
mingħajr disinn fuq in-naħa l-oħra.
4.
TAGĦRIF KLINIKU
4.1
INDIKAZZJONIJIET TERAPEWTIĊI
Sildenafil Teva hu indikat f’irġiel adulti bi problema ta impotenza
fl-irġiel, minħabba li ma jkunx jista’
jilħaq jew iżomm twebbis għal tul ta’ żmien biex l-att sesswali
iseħħ b’mod sodisfaċenti.
Biex Sildenafil Teva ikun effettiv, ikun hemm bżonn ta’
stimulazzjoni sesswali.
4.2
POŻOLOĠIJA U METODU TA’ KIF GĦANDU JINGĦATA
Pożoloġija
_Użu fl-adulti _
Id-doża rrakkomandata hija 50 mg meħuda kif meħtieġ madwar siegħa
qabel l-attività sesswali.
Bażata fuq effiċjenza u tollerabilità, id-doża tista tiżdied
għal 100 mg jew titnaqqas għal 25 mg.
Id-doża massima rrakkomandata hija 100 mg. Il-frekwenza tad-dożagg
mass
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 04-07-2022
Summary of Product characteristics Summary of Product characteristics Bulgarian 04-07-2022
Public Assessment Report Public Assessment Report Bulgarian 30-11-2012
Patient Information leaflet Patient Information leaflet Spanish 04-07-2022
Public Assessment Report Public Assessment Report Spanish 30-11-2012
Patient Information leaflet Patient Information leaflet Czech 04-07-2022
Public Assessment Report Public Assessment Report Czech 30-11-2012
Patient Information leaflet Patient Information leaflet Danish 04-07-2022
Public Assessment Report Public Assessment Report Danish 30-11-2012
Patient Information leaflet Patient Information leaflet German 04-07-2022
Public Assessment Report Public Assessment Report German 30-11-2012
Patient Information leaflet Patient Information leaflet Estonian 04-07-2022
Public Assessment Report Public Assessment Report Estonian 30-11-2012
Patient Information leaflet Patient Information leaflet Greek 04-07-2022
Public Assessment Report Public Assessment Report Greek 30-11-2012
Patient Information leaflet Patient Information leaflet English 04-07-2022
Public Assessment Report Public Assessment Report English 30-11-2012
Patient Information leaflet Patient Information leaflet French 04-07-2022
Public Assessment Report Public Assessment Report French 30-11-2012
Patient Information leaflet Patient Information leaflet Italian 04-07-2022
Public Assessment Report Public Assessment Report Italian 30-11-2012
Patient Information leaflet Patient Information leaflet Latvian 04-07-2022
Public Assessment Report Public Assessment Report Latvian 30-11-2012
Patient Information leaflet Patient Information leaflet Lithuanian 04-07-2022
Summary of Product characteristics Summary of Product characteristics Lithuanian 04-07-2022
Public Assessment Report Public Assessment Report Lithuanian 30-11-2012
Patient Information leaflet Patient Information leaflet Hungarian 04-07-2022
Summary of Product characteristics Summary of Product characteristics Hungarian 04-07-2022
Public Assessment Report Public Assessment Report Hungarian 30-11-2012
Patient Information leaflet Patient Information leaflet Dutch 04-07-2022
Public Assessment Report Public Assessment Report Dutch 30-11-2012
Patient Information leaflet Patient Information leaflet Polish 04-07-2022
Public Assessment Report Public Assessment Report Polish 30-11-2012
Patient Information leaflet Patient Information leaflet Portuguese 04-07-2022
Summary of Product characteristics Summary of Product characteristics Portuguese 04-07-2022
Public Assessment Report Public Assessment Report Portuguese 30-11-2012
Patient Information leaflet Patient Information leaflet Romanian 04-07-2022
Public Assessment Report Public Assessment Report Romanian 30-11-2012
Patient Information leaflet Patient Information leaflet Slovak 04-07-2022
Public Assessment Report Public Assessment Report Slovak 30-11-2012
Patient Information leaflet Patient Information leaflet Slovenian 04-07-2022
Summary of Product characteristics Summary of Product characteristics Slovenian 04-07-2022
Public Assessment Report Public Assessment Report Slovenian 30-11-2012
Patient Information leaflet Patient Information leaflet Finnish 04-07-2022
Public Assessment Report Public Assessment Report Finnish 30-11-2012
Patient Information leaflet Patient Information leaflet Swedish 04-07-2022
Public Assessment Report Public Assessment Report Swedish 30-11-2012
Patient Information leaflet Patient Information leaflet Norwegian 04-07-2022
Summary of Product characteristics Summary of Product characteristics Norwegian 04-07-2022
Patient Information leaflet Patient Information leaflet Icelandic 04-07-2022
Summary of Product characteristics Summary of Product characteristics Icelandic 04-07-2022
Patient Information leaflet Patient Information leaflet Croatian 04-07-2022

Search alerts related to this product